恩格列净对心力衰竭患者心血管和肾脏结局的影响:按基线糖尿病状态分组的EMPEROR-Reduced试验结果
EMPEROR-Reduced试验纳入3730例射血分数降低的心力衰竭患者,随机接受恩格列净10mg每日一次或安慰剂。结果显示,恩格列净在有无糖尿病患者中均降低主要结局风险(HR 0.72与0.78,交互P=0.57),且对心衰住院、肾功能下降及严重肾脏不良结局的获益不受基线糖尿病状态或HbA1c连续值影响。
要点
- 恩格列净在有无糖尿病患者中均显著降低心血管死亡或心衰住院风险。
- 恩格列净对心衰住院、eGFR下降及肾脏不良结局的获益不受基线糖尿病状态影响。
- 基线HbA1c连续值未显著改变恩格列净对主要结局的获益(交互P=0.40)。
核心结论
- 在射血分数降低的心力衰竭患者中,恩格列净显著改善心血管和肾脏结局,且不依赖于基线糖尿病状态和HbA1c水平。
研究设计与样本
- EMPEROR-Reduced试验将3730例NYHA II-IV级、左心室射血分数≤40%的心力衰竭患者随机分配至恩格列净10mg每日一次或安慰剂组,在推荐治疗基础上加用。
主要发现
- 3730例患者中1856例(50%)有糖尿病,1268例(34%)为糖尿病前期(HbA1c 5.7-6.4%),606例(16%)血糖正常(HbA1c <5.7%)。
- 有糖尿病患者的主要结局(心血管死亡或心衰住院)、心衰总住院及肾脏不良结局风险更高,但糖尿病前期与血糖正常患者之间相似。
- 恩格列净在有无糖尿病患者中降低主要结局风险(HR 0.72 [95%CI 0.60-0.87] 与 0.78 [95%CI 0.64-0.97],交互P=0.57)。
- 恩格列净对心衰总住院、eGFR随时间下降及严重肾脏不良结局风险的影响在有无糖尿病患者中无差异,在糖尿病前期或血糖正常患者中亦无差异。
- 基线HbA1c作为连续变量未显著改变恩格列净对主要结局的获益(交互P=0.40)。
关键数值与推荐
- 恩格列净未降低糖尿病前期或血糖正常患者的HbA1c,且未增加低血糖风险。
临床怎么用
- 对于射血分数降低的心力衰竭患者,无论基线是否合并糖尿病或处于糖尿病前期,均可考虑使用恩格列净以改善心血管和肾脏结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients with heart failure with reduced ejection fraction, but additional information is needed about whether glycemic status influences the magnitude of their benefits on heart failure and renal events. METHODS: Patients with Class II-IV heart failure and a left ventricular ejection fraction ≤40% were randomized to receive empagliflozin (10 mg daily) or placebo in addition to recommended therapy. We prespecified a comparison of the effect of empagliflozin in patients with and without diabetes. RESULTS: Of the 3730 patients enrolled, 1856 (50%) had diabetes, 1268 (34%) had prediabetes (hemoglobin A1c [HbA1c] 5.7-6.4%), and 606 (16%) had normoglycemia (HbA1c <5.7%). The risks of the primary outcome (cardiovascular death or hospitalization for heart failure), total hospitalizations for heart failure, and adverse renal outcomes were higher in patients with diabetes, but were similar between patients with prediabetes and normoglycemia. Empagliflozin reduced the risk of the primary outcome in patients with and without diabetes (hazard ratio, 0.72 [95% CI, 0.60-0.87] and 0.78 [95% CI, 0.64-0.97], respectively, P-interaction=0.57). Patients with and without diabetes also did not differ with respect to the effect of empagliflozin on total hospitalizations for heart failure, on the decline in estimated glomerular filtration rate over time, and on the risk of serious adverse renal outcomes. Among these end points, the effects of the drug did not differ in patients with prediabetes or normoglycemia. When analyzed as a continuous variable, baseline HbA1c did not significantly modify the benefits of empagliflozin on the primary outcome (P-interaction=0.40). Empagliflozin did not lower HbA1c in patients with prediabetes or normoglycemia and was not associated with increased risk of hypoglycemia. CONCLUSIONS: In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction), empagliflozin significantly improved cardiovascular and renal outcomes in patients with heart failure and a reduced ejection fraction, independent of baseline diabetes status and across the continuum of HbA1c. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057977.
引用
- Anker SD, Butler J, Filippatos G, et al. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. Circulation. 2020. PMID: 33175585. doi:10.1161/CIRCULATIONAHA.120.051824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。